Victory Capital Management Inc. Sells 2,167 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Victory Capital Management Inc. reduced its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 3.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,630 shares of the company’s stock after selling 2,167 shares during the quarter. Victory Capital Management Inc.’s holdings in Myriad Genetics were worth $1,578,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. GSA Capital Partners LLP acquired a new stake in shares of Myriad Genetics during the 3rd quarter valued at about $505,000. State of New Jersey Common Pension Fund D bought a new position in Myriad Genetics in the 3rd quarter worth approximately $1,965,000. Atria Investments Inc lifted its stake in shares of Myriad Genetics by 5.4% during the third quarter. Atria Investments Inc now owns 11,414 shares of the company’s stock valued at $313,000 after acquiring an additional 581 shares during the period. New York State Teachers Retirement System boosted its stake in shares of Myriad Genetics by 4.4% in the 3rd quarter. New York State Teachers Retirement System now owns 73,900 shares of the company’s stock valued at $2,024,000 after purchasing an additional 3,102 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Myriad Genetics by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,468 shares of the company’s stock valued at $478,000 after acquiring an additional 6,834 shares during the last quarter. Institutional investors own 99.02% of the company’s stock.

Insider Buying and Selling at Myriad Genetics

In other Myriad Genetics news, Director Colleen F. Reitan sold 46,012 shares of Myriad Genetics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the transaction, the director now directly owns 42,533 shares of the company’s stock, valued at $1,188,797.35. The trade was a 51.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction on Friday, October 11th. The stock was sold at an average price of $22.93, for a total value of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares in the company, valued at approximately $22,067,327.54. This trade represents a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,012 shares of company stock valued at $1,900,485 in the last quarter. Company insiders own 2.10% of the company’s stock.

Myriad Genetics Trading Up 1.4 %

Shares of Myriad Genetics stock opened at $15.71 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The firm has a 50-day moving average of $22.02 and a 200-day moving average of $24.42. Myriad Genetics, Inc. has a 52-week low of $14.72 and a 52-week high of $29.30. The stock has a market cap of $1.43 billion, a PE ratio of -12.08 and a beta of 1.93.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MYGN shares. Piper Sandler decreased their target price on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. StockNews.com lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Scotiabank increased their price objective on shares of Myriad Genetics from $29.00 to $34.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. raised their target price on shares of Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a research note on Wednesday, August 7th. Finally, Morgan Stanley reduced their price target on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $27.36.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.